Low-level viremia in hep B (HBV): Robert S. Brown, Jr., MD, MPH, on possible causes and when to switch to entecavir, tenofovir, or combination therapy
Susanna Naggie, MD, MHS, on HCV and HIV coinfection FAQs and challenges. Guideline-based strategies, common DAA and ART drug interactions (DDIs).
Deciding between TAF, TDF, and entecavir: Jordan J. Feld, MD, MPH, outlines clinical scenarios where he recommends a specific first-line HBV therapy.
Tool, education to avoid drug interactions, follow guidelines when choosing anti-HCV DAA and anti-HIV ART drugs for patients with HCV/HIV coinfection.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.